Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
Authors
Keywords
Cyclin D1, P27, Ki67, Statins, Breast cancer
Journal
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-29
DOI
10.1186/s12967-015-0486-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Palbociclib: First Global Approval
- (2015) Sohita Dhillon DRUGS
- Statins and breast cancer prognosis: evidence and opportunities
- (2014) Thomas P Ahern et al. LANCET ONCOLOGY
- Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland
- (2014) Teemu J. Murtola et al. PLoS One
- Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
- (2013) Olöf Bjarnadottir et al. BREAST CANCER RESEARCH AND TREATMENT
- Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative
- (2013) P. Desai et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology
- (2013) E. R. Nelson et al. SCIENCE
- Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice
- (2012) Altaf Mohammed et al. INTERNATIONAL JOURNAL OF CANCER
- Statin Use and Reduced Cancer-Related Mortality
- (2012) Sune F. Nielsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting tumor cell metabolism with statins
- (2012) J W Clendening et al. ONCOGENE
- Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
- (2011) B. Glimelius et al. ANNALS OF ONCOLOGY
- Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway
- (2011) Wen-Bin Zhong et al. BIOCHEMICAL PHARMACOLOGY
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- (2011) Elisabeth Luporsi et al. BREAST CANCER RESEARCH AND TREATMENT
- The Oxysterol, 27-Hydroxycholesterol, Links Cholesterol Metabolism to Bone Homeostasis Through Its Actions on the Estrogen and Liver X Receptors
- (2011) Erik R. Nelson et al. ENDOCRINOLOGY
- Simvastatin Maintains Osteoblastic Viability While Promoting Differentiation by Partially Regulating the Expressions of Estrogen Receptors α
- (2011) Jun-Beom Park et al. JOURNAL OF SURGICAL RESEARCH
- Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
- (2011) T. P. Ahern et al. JNCI-Journal of the National Cancer Institute
- Switching cyclin D-Cdk4 kinase activity on and off
- (2010) Stacy Blain CELL CYCLE
- Pleiotropic Effects of Statins
- (2010) Qian Zhou et al. CIRCULATION JOURNAL
- Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
- (2009) Elisabeth R. Garwood et al. BREAST CANCER RESEARCH AND TREATMENT
- Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes
- (2009) Hashem B. El–Serag et al. GASTROENTEROLOGY
- p27Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis
- (2009) Xiaoxiang Guan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Immunohistochemically Determined Estrogen Receptor Phenotype Remains Stable in Recurrent and Metastatic Breast Cancer
- (2008) Carmen Gomez-Fernandez et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Statins and cancer: A systematic review and meta-analysis
- (2008) Jaana Kuoppala et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started